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The effect of the newly developed, up to the present most
potent and selective enhancer substance, R-(-)-1-(benzo-
furan-2-yl)-2-propylaminopentane [(-)-BPAP], was stud-
ied in rats exposed to an experimental stroke. Permanent
focal ischemia was induced by cortical photothrombosis
in Wistar rats with Rose Bengal (20 mg/kg, i.v.), irradiated
by a cold light source for 10 min. Rats were treated daily
with (-)-BPAP (0.2 mg/kg, i.p.) for 3 days. The infarction
was visualized with 2% TTC. The lesion size was evaluated
by morphometry using image analysis software (AxioVi-
son/Zeiss). The effect of (-)-BPAP on the learning ability
of rats was measured in the shuttle box. The acquisition of
a two-way conditioned avoidance reflex (CAR) was ana-
lyzed during 5 consecutive days. The rats were trained
with 100 trials per day. The light-irradiation for 10 min
after injection of Rose Bengal caused well-demarcated tis-
sue damage in the cerebral cortex and decreased the per-
formance of the lesioned rats in the shuttle box. (-)-BPAP
treatment caused a statistically significant reduction of the
infarct size (from 1.190 ± 0.096 mm2 to 0.256 ± 0.057
mm2; n = 18) and improved the performance of the rats
(45.75 ± 15 to 75.67 ± 7.2; n = 12). The data are in excel-
lent harmony with the series of papers which described
the protective effect of (-)-BPAP in various types of
enhancer-sensitive cultured cells.
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